Latest 5-HT3 antagonist Stories
Helsinn Healthcare and Eisai have announced the availability in the US of Aloxi injection 0.075mg for the prevention of postoperative nausea and vomiting for up to 24 hours following surgery. Approved by the FDA for postoperative nausea and vomiting, Aloxi injection 0.075mg is administered as a single IV dose immediately before induction of anesthesia to prevent PONV for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated. Aloxi has been available in the US...
AP Pharma has completed patient enrollment in its pivotal Phase III study in chemotherapy-induced nausea and vomiting comparing the efficacy of APF530 with Aloxi for the prevention of acute and delayed onset chemotherapy-induced nausea and vomiting in both moderate and highly emetogenic chemotherapy treatments. The trial is being conducted in the US, India and Poland. Data collection will be finalized following completion of treatment of the last patients, expected near the end of July 2008....
Investor Relations Contacts: Lippert/Heilshorn & Associates Don Markley, 310-691-7100 dmarkley@lhai.com or Company Contacts: A.P. Pharma, Inc. Gregory Turnbull, President and Chief Executive Officer 650-366-2626 Logo: http://www.appharma.com A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceutical company, has completed patient enrollment in its pivotal Phase 3 study in chemotherapy-induced nausea and vomiting (CINV) comparing the efficacy of APF530 (a proprietary, sustained...
WARREN, N.J. and PORTAGE, Ind., June 17 /PRNewswire/ -- MonoSol Rx, a drug delivery company specializing in dissolving thin film pharmaceutical products, and Strativa Pharmaceuticals, the proprietary products division of a wholly owned subsidiary of Par Pharmaceutical Companies, Inc. , announced today that they have entered into an exclusive licensing agreement under which Strativa has acquired the U.S. commercialization rights to the thin film formulation of ondansetron from MonoSol Rx....
WOODCLIFF LAKE, N.J., June 17 /PRNewswire-FirstCall/ -- Strativa Pharmaceuticals, the proprietary products division of a wholly owned subsidiary of Par Pharmaceutical Companies, Inc. , and MonoSol Rx today announced that they have entered into an exclusive licensing agreement under which Strativa has acquired the commercialization rights in the United States and its territories to the thin film formulation of ondansetron from MonoSol Rx, a leader in oral thin film technology. Ondansetron...
Merck & Co., Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved EMEND(R) (fosaprepitant dimeglumine) for Injection, a new intravenous therapy for the prevention of chemotherapy-induced nausea and vomiting (CINV). EMEND for Injection is an intravenous prodrug of the oral formulation of EMEND(R) (aprepitant), which means that when EMEND for Injection is administered, fosaprepitant is rapidly converted in the body to aprepitant. EMEND for Injection is approved for...
By Karla Gale NEW YORK (Reuters Health) - For people undergoing surgery, recovery could be easier with a new anti-nausea drug. Aprepitant, made by Merck Research Laboratories, reduces the rate of vomiting during the first 48 hours after open abdominal surgery, according to a trial reported this week at the meeting of the American Society of Anesthesiologists in Atlanta. The drug is already approved by the US Food and Drug Administration for treatment of chemotherapy-induced nausea and...
By reading this article and writing a practice profile, you can gain a certificate of learning. You have up to a year to send in your practice profile. Guidelines on how to write and submit a profile are featured at the end of this article. Summary For patients with terminal illness, nausea and vomiting can be very distressing symptoms and can have a negative effect on their quality of life. This article discusses the nursing management of these symptoms, with a view to improving quality of...
